211 related articles for article (PubMed ID: 29496990)
21. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer.
Oh JR; Byun BH; Hong SP; Chong A; Kim J; Yoo SW; Kang SR; Kim DY; Song HC; Bom HS; Min JJ
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1459-68. PubMed ID: 21505897
[TBL] [Abstract][Full Text] [Related]
22. The Diagnostic Usefulness of
Spanu A; Nuvoli S; Marongiu A; Gelo I; Mele L; De Vito A; Rondini M; Madeddu G
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441438
[No Abstract] [Full Text] [Related]
23. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
24. Clinical applications of single-photon emission computed tomography/computed tomography in post-ablation
Jiang L; Xiang Y; Huang R; Tian R; Liu B
Pediatr Radiol; 2021 Aug; 51(9):1724-1731. PubMed ID: 33759024
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management.
Song H; Mosci C; Akatsu H; Basina M; Dosiou C; Iagaru A
Clin Nucl Med; 2018 Oct; 43(10):705-709. PubMed ID: 30153149
[TBL] [Abstract][Full Text] [Related]
27. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
[TBL] [Abstract][Full Text] [Related]
28. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
29. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
30. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
31. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
[TBL] [Abstract][Full Text] [Related]
32. [Contribution of computed tomography in patients with lung metastases of differentiated thyroid carcinoma not apparent on plain radiography who were treated with radioiodine].
Rosário PW; Tavares WC; Barroso AL; Rezende LL; Padrão EL; Purisch S
Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):114-9. PubMed ID: 18345404
[TBL] [Abstract][Full Text] [Related]
33. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
34. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
35. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.
Tharp K; Israel O; Hausmann J; Bettman L; Martin WH; Daitzchman M; Sandler MP; Delbeke D
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1435-42. PubMed ID: 15221294
[TBL] [Abstract][Full Text] [Related]
36. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
37. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
38. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients.
Blum M; Tiu S; Chu M; Goel S; Friedman K
Thyroid; 2011 Nov; 21(11):1235-47. PubMed ID: 22007920
[TBL] [Abstract][Full Text] [Related]
39. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
Kist JW; de Keizer B; van der Vlies M; Brouwers AH; Huysmans DA; van der Zant FM; Hermsen R; Stokkel MP; Hoekstra OS; Vogel WV; ;
J Nucl Med; 2016 May; 57(5):701-7. PubMed ID: 26609180
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
